These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 9834048)

  • 1. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.
    Greenblatt DJ; Harmatz JS; von Moltke LL; Ehrenberg BL; Harrel L; Corbett K; Counihan M; Graf JA; Darwish M; Mertzanis P; Martin PT; Cevallos WH; Shader RI
    Clin Pharmacol Ther; 1998 Nov; 64(5):553-61. PubMed ID: 9834048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem.
    Drover D; Lemmens H; Naidu S; Cevallos W; Darwish M; Stanski D
    Clin Ther; 2000 Dec; 22(12):1443-61. PubMed ID: 11192136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone.
    Drover DR
    Clin Pharmacokinet; 2004; 43(4):227-38. PubMed ID: 15005637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance.
    Troy SM; Lucki I; Unruh MA; Cevallos WH; Leister CA; Martin PT; Furlan PM; Mangano R
    J Clin Psychopharmacol; 2000 Jun; 20(3):328-37. PubMed ID: 10831020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance.
    Verster JC; Volkerts ER; Schreuder AH; Eijken EJ; van Heuckelum JH; Veldhuijzen DS; Verbaten MN; Paty I; Darwish M; Danjou P; Patat A
    J Clin Psychopharmacol; 2002 Dec; 22(6):576-83. PubMed ID: 12454557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Mertzanis P; Graf JA; Durol AL; Counihan M; Roth-Schechter B; Shader RI
    Clin Pharmacol Ther; 1998 Dec; 64(6):661-71. PubMed ID: 9871431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening.
    Zammit GK; Corser B; Doghramji K; Fry JM; James S; Krystal A; Mangano RM
    J Clin Sleep Med; 2006 Oct; 2(4):417-23. PubMed ID: 17557470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon.
    Stone BM; Turner C; Mills SL; Paty I; Patat A; Darwish M; Danjou P
    Br J Clin Pharmacol; 2002 Feb; 53(2):196-202. PubMed ID: 11851645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different types of GABA(A) receptors may mediate the anticonflict and response rate-decreasing effects of zaleplon, zolpidem, and midazolam in squirrel monkeys.
    Paronis CA; Cox ED; Cook JM; Bergman J
    Psychopharmacology (Berl); 2001 Aug; 156(4):461-8. PubMed ID: 11498724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of two benzodiazepine receptor agonist hypnotics on sleep-dependent memory consolidation.
    Hall-Porter JM; Schweitzer PK; Eisenstein RD; Ahmed HA; Walsh JK
    J Clin Sleep Med; 2014 Jan; 10(1):27-34. PubMed ID: 24426817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons.
    Ator NA
    Drug Alcohol Depend; 2000 Dec; 61(1):55-68. PubMed ID: 11064184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration.
    Greenblatt DJ; Harmatz JS; Singh NN; Steinberg F; Roth T; Moline ML; Harris SC; Kapil RP
    J Clin Pharmacol; 2014 Mar; 54(3):282-90. PubMed ID: 24203450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem.
    Sanger DJ; Morel E; Perrault G
    Eur J Pharmacol; 1996 Oct; 313(1-2):35-42. PubMed ID: 8905326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of benzodiazepines and the non-benzodiazepine agents zolpidem and zaleplon with respect to anxiolytic action as measured by increases in hypertonic NaCl-solution drinking in rats.
    Lobarinas E; Falk JL
    Psychopharmacology (Berl); 2000 Apr; 149(2):176-80. PubMed ID: 10805613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening.
    Danjou P; Paty I; Fruncillo R; Worthington P; Unruh M; Cevallos W; Martin P
    Br J Clin Pharmacol; 1999 Sep; 48(3):367-74. PubMed ID: 10510148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences.
    Greenblatt DJ; Harmatz JS; von Moltke LL; Wright CE; Durol AL; Harrel-Joseph LM; Shader RI
    J Pharmacol Exp Ther; 2000 May; 293(2):435-43. PubMed ID: 10773013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zaleplon and triazolam in humans: acute behavioral effects and abuse potential.
    Rush CR; Frey JM; Griffiths RR
    Psychopharmacology (Berl); 1999 Jul; 145(1):39-51. PubMed ID: 10445371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminative stimulus effects of benzodiazepine (BZ)(1) receptor-selective ligands in rhesus monkeys.
    McMahon LR; Gerak LR; Carter L; Ma C; Cook JM; France CP
    J Pharmacol Exp Ther; 2002 Feb; 300(2):505-12. PubMed ID: 11805210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine.
    Cysneiros RM; Farkas D; Harmatz JS; von Moltke LL; Greenblatt DJ
    Clin Pharmacol Ther; 2007 Jul; 82(1):54-62. PubMed ID: 17443132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic profile of SKP-1041, a modified release formulation of zaleplon.
    Greenblatt DJ; Harmatz JS; Walsh JK; Luthringer R; Staner L; Otmani S; Nedelec JF; Francart C; Parent SJ; Staner C
    Biopharm Drug Dispos; 2011 Dec; 32(9):489-97. PubMed ID: 21935965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.